9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Settlement Agreement with GSK - REGENXBIO Inc. to Pay $10 Million
Financial Results, Press Release
Announces Regulatory Update on RGX-121 BLA for MPS II
Announces Regulatory Update on Ultra Rare MPS Programs
Reports Third Quarter 2025 Financial Results and Operational Highlights
Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II
Reports Second Quarter 2025 Financial Results and Operational Highlights
Shareholder votes
FY 2025
Q3
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities to be Offered to Employees
PRE 14A
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
Correspondence
Submission Upload
Automatic Shelf Registration Statement
Post-Effective Amendment to Registration Statement